NCT06826326

Neuroimaging of Escitalopram in Autism Spectrum Disorder

Enrolling by Invitation
PHASE2Ages 12–17InterventionalBasic science
Kathryn Unruh
~5 participants
Updated 2026-02-18 on ClinicalTrials.gov
What's tested:Escitalopram 10mgPlacebo

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Rewarded Antisaccade task
Measured over At Visit 2 (1 day to 1 month after Screening/Visit 1) and Visit 3 (5 days to 3 weeks after Visit 2)
Autism Spectrum Disorder

NCT06826326

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Hoglund Biomedical Imaging Center

    Kansas City, Kansasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Kathryn E Unruh, PhD · PRINCIPAL_INVESTIGATOR · University of Kansas

This trial hasn't published a contact. View it on ClinicalTrials.gov

  • Rewarded Antisaccade taskAt Visit 2 (1 day to 1 month after Screening/Visit 1) and Visit 3 (5 days to 3 weeks after Visit 2)

    During the rewarded antisaccade task (R-ANTI), participants are instructed to look away from a peripheral target and to the mirror location in the opposite hemifield (antisaccade) and avoid looking toward the peripheral target (prosaccade). Two trial types are presented: reward and no-reward. Number of prosaccades is compared between reward and no-reward trial types.